It’s not that AE37 doesn’t work on higher her2 expressing breast cancer patients, it’s that those control patients received Herceptin which is very effective. So DFS didn’t get the p value to show improvement. That was more of a trial design error much discussed in the past. Triple negative patients don’t benefit from Herceptin so we see a clearer comparison to access the vaccine.